Continuing its interest in gene therapies for rare diseases, Takeda has committed up to US$400 M, with an undisclosed double-digit million-dollar upfront payment and research funding payments, to access Evozyne’s protein design platform. The companies will leverage this technology to research and develop next-generation gene therapies for up to four rare disease targets. This deal builds upon a previous agreement between the two companies, announced in January 2021, that involves the research and development of gene therapy proteins for metabolic diseases.